PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Clinical research on psychedelics gets a boost from new study

Consensus on how mindset and surroundings shape therapy outcomes is an important step toward regulatory approval for use of drugs like MDMA and psilocybin in treatment of debilitating mental health conditions

2025-06-03
(Press-News.org) As psychedelics gain traction as potential treatments for mental health disorders, an international study led by researchers at McGill University, Imperial College London, and the University of Exeter stands to improve the rigour and reliability of clinical research.

Up to now, psychedelic clinical trials have had what has been widely acknowledged as a critical flaw: the failure to properly account for how a person’s mindset and surroundings influence the effects of psychedelics such as MDMA and psilocybin. This gap has led to inconsistent study results, making regulatory approval more difficult.

To address this, the researchers conducted a Delphi consensus study, bringing together 89 experts from 17 countries for a multi-round debate. The result is the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, published in Nature Medicine, a 30-item checklist, representing the first global agreement on which psychosocial factors have the greatest impact on a psychedelic experience.

“For decades, we’ve known that psychedelics don’t work in isolation. The person’s mindset, the therapy room, even the music playing all influence outcomes,” said co-lead author Chloé Pronovost-Morgan, a researcher at McGill University and Imperial College London. “Two trials using the same psychedelic drug, at the same dose, can produce completely different results depending on the environment.”

This approach challenges the way psychoactive drugs are typically studied, where scientists try to control or eliminate outside variables to isolate a drug’s effects. These guidelines recognize that context is crucial and should be studied directly.

Why guidelines matter By offering a standard framework for evaluating and reporting these variables, the guidelines aim to make trial outcomes more consistent and comparable across studies.

Leor Roseman from the University of Exeter is co-senior author and said: “Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications. Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics.”

The lack of standards has had consequences beyond the research lab, Pronovost-Morgan explained. The U.S. Food and Drug Administration recently rejected MDMA-assisted therapy for post-traumatic stress disorder, citing inconsistent reporting across trials as a key reason for the decision.

“There is immense public interest in psychedelic therapies, particularly for individuals suffering from debilitating mental health conditions like PTSD, depression and anxiety, which have not responded to existing treatments,” said co-senior author Kyle Greenway, Assistant Professor in McGill’s Division of Social and Transcultural Psychiatry and a researcher at the Lady Davis Institute for Medical Research.

“Our guidelines offer a new gold standard for psychedelic research, helping bring these treatments to those who need them most.”

The research team is organizing a three-day workshop in October, funded by McGill’s Healthy Brains, Healthy Lives initiative, where leading experts in psychedelics and neuroscience will discuss how the guidelines can be integrated into research and clinical practice.

About the study

“The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) Guidelines: An international Delphi consensus study” by Chloé Pronovost-Morgan, Kyle Greenway and Leor Roseman was published in Nature Medicine.

This research was supported by the Imperial College London Societal Engagement Seed Fund.

END


ELSE PRESS RELEASES FROM THIS DATE:

Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical

2025-06-03
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129. EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those ...

African swine fever not recently imported to Europe, has been around for years

2025-06-03
A new study in Genome Biology and Evolution, published by Oxford University Press, finds that the African Swine Fever virus, currently circulating in Europe, is not the result of a recent introduction. Instead, the virus has been present in the region since 2007. Its current dramatic spread appears to be driven largely by people within Europe traveling longer distances. African Swine Fever virus is a highly virulent DNA virus that causes a severe hemorrhagic disease of the same name affecting both domestic pigs and wild boars. The disease is characterized by high mortality rates, leading to significant economic losses in the pork industry. According to estimates ...

APA calls for guardrails, education, to protect adolescent AI users

2025-06-03
The effects of artificial intelligence on adolescents are nuanced and complex, according to a report from the American Psychological Association that calls on developers to prioritize features that protect young people from exploitation, manipulation and the erosion of real-world relationships. “AI offers new efficiencies and opportunities, yet its deeper integration into daily life requires careful consideration to ensure that AI tools are safe, especially for adolescents,” according to the report, entitled “Artificial Intelligence and Adolescent Well-being: An APA ...

Wendelstein 7-X sets new performance records in nuclear fusion research

2025-06-03
On the path toward a fusion power plant, stellarators are among the most promising concepts. In the future, they could generate usable energy by fusing light atomic nuclei. This reaction must take place in a plasma — a hot gas of ionized particles heated to many tens of millions of degrees Celsius. Stellarators use magnetic confinement to hold the plasma: the plasma is trapped by a complex and powerful magnetic field, floating inside a donut-shaped vacuum chamber. With Wendelstein 7-X (W7-X), the Max Planck Institute for Plasma Physics (IPP) in Greifswald, with support from the European fusion consortium EUROfusion, is operating the world's ...

Brain connections at 3 months predict infant emotional development

2025-06-03
PITTSBURGH, Pennsylvania, USA, 3 June 2025 – In a comprehensive Genomic Press research article, scientists have uncovered remarkable insights into how the earliest brain connections shape infant emotional development, potentially offering new ways to identify children at risk for future behavioral and emotional challenges. The groundbreaking study, led by Dr. Yicheng Zhang and Dr. Mary L. Phillips at the University of Pittsburgh School of Medicine, examined 95 infant-caregiver pairs using advanced brain imaging techniques. Researchers discovered that the microstructure of white matter ...

Listening to life: Speech technology transforms clinical research

2025-06-03
ATLANTA, Georgia, USA, 3 June 2025 – In a comprehensive Genomic Press interview published today in Psychedelics, Dr. Deanna M. Kaplan reveals how her journey from journalism student to clinical psychologist led to revolutionary advances in capturing human experiences through voice technology. As Assistant Professor at Emory University School of Medicine and Director of Health Technologies for Spiritual Health at Emory Healthcare, Dr. Kaplan has transformed how researchers understand the impact of clinical ...

ECT sessions shape depression treatment outcomes

2025-06-03
HEFEI, Anhui, China, 3 June 2025 – In a comprehensive peer-reviewed Genomic Press Thought Leaders Invited Review, researchers have unveiled critical insights into how the number of electroconvulsive therapy (ECT) sessions influences treatment outcomes for depression, potentially transforming clinical decision-making for one of psychiatry's most effective yet controversial treatments. The review, published in Brain Medicine, synthesizes decades of research to address a fundamental question that has long puzzled clinicians: How many ECT sessions are optimal for treating severe depression while minimizing cognitive side effects? "ECT is like a powerful ...

Psilocybin enters gastroenterology: First-ever psychedelic study targets treatment-resistant IBS

2025-06-03
BOSTON, Massachusetts, USA, 3 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Erin E. Mauney reveals how her pioneering research brings psychedelic medicine into gastroenterology for the first time, potentially transforming treatment for millions suffering from intractable irritable bowel syndrome (IBS). The assistant professor of pediatrics at Tufts University, who maintains a research appointment at Massachusetts General Hospital, leads the first clinical trial examining psilocybin's effects on treatment-resistant IBS. Her work addresses a critical gap in medicine: the substantial population ...

Renowned psychiatrist illuminates biological roots of mental illness through pioneering research

2025-06-03
MILANO, Italy, 3 June 2025 – In a comprehensive Genomic Press Interview published in Brain Medicine, Professor Francesco Benedetti shares his transformative journey from confronting childhood awareness of mental illness to becoming a leading figure in psychiatric research. As founder and leader of the Psychiatry & Clinical Psychobiology research unit at IRCCS Ospedale San Raffaele, Dr. Benedetti has dedicated decades to reclaiming psychiatry's rightful place within medical science. Professor ...

Ancient collagen can help identify a “wombat the size of a hippo” in the fossil record

2025-06-03
What happened to all the megafauna? From moas to mammoths, many large animals went extinct between 50 and 10,000 years ago. Learning why could provide crucial evidence about prehistoric ecosystems and help us understand future potential extinctions. But surviving fossils are often too fragmented to determine the original species, and DNA is not always recoverable, especially in hot or damp environments. Now scientists have isolated collagen peptide markers which allow them to identify three key megafauna ...

LAST 30 PRESS RELEASES:

Poll: Amid multi-state measles outbreak, 79% of Americans support routine childhood vaccine requirements

Artificial intelligence in miniature format for small devices

Early blood-thinning treatment safe and effective for stroke patients

New gene therapy delivery device could let hospitals create personalized nanomedicines on-demand

Membrane or metabolism, which came first?

Jackpot! Gold from e-waste opens a rich vein for miners and the environment

EPFL scientists build first self-illuminating biosensor

Oxford scientists develop new technique for capturing ultra-intense laser pulses in a single shot

Inflammatory cells remain in the blood after treatment of severe asthma

New insights into seasonal shifts in sleep

Estimating microbial biomass from air-dried soils: A safer, scalable approach

AI in healthcare needs patient-centred regulation to avoid discrimination – new commentary

A good soak in a hot tub might beat a sauna for health benefits

Surgery plus speech therapy linked to improved language after stroke

GP performance pay fails to drive lasting changes in quality of care

Focusing on weight loss alone for obesity may do more harm than good

In sub-Saharan Africa, 1 in 6 cancer medications found to be defective

Newborns require better care to improve survival and long-term health

EMBARGOED: New study shows almost half of hospital patients in Malawi and Tanzania have multiple health conditions

People with symptoms of chronic lung disease in Kenya face ‘catastrophic’ health costs

Sylvester Cancer Tip Sheet - June 2025

UC Davis and Proteus Space to launch first-ever dynamic digital twin into space

Olympians' hearts in focus: groundbreaking study reveals elite rowers' surprising AFib risk

Common medicine for autoimmune diseases works on giant cell arteritis

Your neighborhood may be tied to risk of inflammation, dementia biomarkers

AAN issues position statement on possible therapies for neurological conditions

Liver organoid breakthrough: Generating organ-specific blood vessels

LRA awards 2025 Lupus Insight Prize to Dr. Deepak Rao for uncovering key drivers of immune imbalance in lupus

Terasaki Institute’s Dr. Yangzhi Zhu recognized as 2024 Biosensors Young Investigator Award Recipient

NAU researchers launch open-source robotic exoskeleton to help people walk

[Press-News.org] Clinical research on psychedelics gets a boost from new study
Consensus on how mindset and surroundings shape therapy outcomes is an important step toward regulatory approval for use of drugs like MDMA and psilocybin in treatment of debilitating mental health conditions